Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte BLOG

Dr. Allan Jordan of Cancer Research UK Interviewed by Mendelspod
WEDNESDAY, NOVEMBER 30, 2016
linkedin twitter facebook |  40Shares

Allan Jordan is Head of Chemistry, Drug Discovery Unit of Cancer Research UK (CRUK) Manchester institute, the largest single disease research charity in the world. He is also a Labcyte customer who was profiled in an award-winning video where he discussed how he used the Echo® Liquid Handler to advance his research and drug discovery work.


Dr. Jordan was recently interviewed by Mendelspod about the charity, which raises more than £500 million per year from public funding and focuses on basic research and drug discovery on all types of cancer. Their goal is to use that information to develop the next generation of medicines to treat patients.


CRUK is unique, says Jordan, because its researchers have complete flexibility in terms of the projects they work on and they can take on more risky projects that might be unattractive to industry. They work to de-risk and develop the best targets to give the maximum benefits to patients without being tied to any specific type of cancer or type of target. (His team uses the Labcyte Echo® 550 to accelerate compound screening).


Jordan is encouraged by early results using genomics, but believes we still have a lot to learn about precision medicine and exactly how it will work. “I think the more we understand that genetic complexity -- the more we learn how to deal with that genetic complexity and how better to use targeted therapies in combination with other targeted therapies -- I think that will start to bring a second revolution in which we see those survival rates start to increase dramatically, we’re starting to see it.”


He says he believes we’re at the “end of the beginning” in figuring out how to put an end to cancer. Labcyte is proud to sponsor the podcast; you can listen to it here.